Pub. Date : 2022 Jul 1
PMID : 35389944
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | OBJECTIVES: Interpatient variability in tacrolimus pharmacokinetics is attributed to metabolism by cytochrome P-450 3A4/5 isoenzymes (encoded by CYP3A4 and CYP3A5). | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | OBJECTIVES: Interpatient variability in tacrolimus pharmacokinetics is attributed to metabolism by cytochrome P-450 3A4/5 isoenzymes (encoded by CYP3A4 and CYP3A5). | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | Guidelines for adjusting tacrolimus based on CYP3A5 test results are published; however, CYP3A4 variants also contribute to the variability in tacrolimus pharmacokinetics. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | The objective of this study is to investigate the impact of both increased and decreased function CYP3A variants on weight and dose-adjusted tacrolimus concentration (C0/D). | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 6 | CONCLUSION: These data indicate that a composite CYP3A phenotype incorporating both increase and decrease variant information from CYP3A4 in addition to CYP3A5 may significantly influence tacrolimus C0/D during the early postoperative period. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 7 | CONCLUSION: These data indicate that a composite CYP3A phenotype incorporating both increase and decrease variant information from CYP3A4 in addition to CYP3A5 may significantly influence tacrolimus C0/D during the early postoperative period. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |